All In Biotech

Drug Trial Radar · NCT00266136

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose Chemotherapy With Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Oct 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,500

Actual

Start

Jun 1999

Primary completion

Jan 2007

Study completion Oct 2012

Sponsor

Lead sponsor
University Hospital MuensterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany); German Federal Ministry of Education and Research
First posted
Dec 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologous stem cell transplantation.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • CytarabineDrug

    see protocol

  • ThioguanineDrug

    see protocol

  • DaunorubicinDrug

    see protocol

  • CyclophosphamideDrug

    see protocol

  • G-CSFDrug

    see protocol

  • Autologous stem cell transplantationProcedure

    for details see protocol

  • Allogeneic stem cell transplantationProcedure

    for details see protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remission rate, Remission duration,Relapse-free survival, Overall survival, Event-free survivalTime frame: 12-18months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.